LSKL TFA NEW
| Price | $38 | $82 | $117 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-13 |
Product Details
| Product Name: LSKL TFA | CAS No.: 2828433-17-4 |
| Purity: 99.33% | Supply Ability: 10g |
| Release date: 2025/05/13 |
Product Introduction
Bioactivity
| Name | LSKL TFA |
| Description | LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a LAP-TGFβ derivative and a TGF-β1 antagonist that can cross the blood-brain barrier, inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis, inhibits subarachnoid fibrosis by inhibiting TSP-1-mediated TGF-β1 activity, prevents the occurrence of chronic hydrocephalus and improves long-term neurocognitive deficits after subarachnoid hemorrhage. |
| In vitro | LSKL TFA from the latent form of TGF-β is responsible for the interaction with the KTFR sequence from ADAMTS1, leading to TGF-β activation. There is a stable binding mode between LSKL, Inhibitor of Thrombospondin (TSP-1) and ADAMTS1 KTFR sequence, characterized by 3 salt bridges and 2 hydrogen bonds. [3] |
| In vivo | Intraperitoneal injection of 1 mg/kg LSKL TFA, into male rats exerted a protective effect against subarachnoid fibrosis, attenuated ventricular enlargement, and effectively inhibited the development of hydrocephalus. [1] Intraperitoneal injection of 30 mg/kg LSKL TFA, was able to successfully inhibit the Smad signaling pathway activated by transforming growth factor-β (TGF-β) after partial hepatectomy. LSKL effectively attenuated the activation of TGF-β-Smad signaling by antagonizing TSP-1 rather than reducing TSP-1 protein expression. [2] |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 200 mg/mL, (349.27 mM.), Sonication is recommended. H2O : 80 mg/mL (139.71 mM.), Sonication is recommended. |
| Keywords | TGF-β1 | TGF-β/Smad | TGF-β Receptor | TGFβ | TGFbeta/Smad | TGF-beta | TGFbeta | TGF-b/Smad | TGFb | Smad | LSKL, Inhibitor of Thrombospondin (TSP1) (TFA) | LSKL, Inhibitor of Thrombospondin (TSP-1) | LSKL, Inhibitor of Thrombospondin (TSP 1) (TFA) |
| Inhibitors Related | Monocrotaline | DMH-1 | Hydrochlorothiazide | Chebulinic acid | Chromenone 1 | LY-364947 | BMP signaling agonist sb4 | Pirfenidone | A 83-01 | Galunisertib | Alantolactone | Halofuginone |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Ovarian Cancer Compound Library | Peptide Compound Library | Bioactive Compounds Library Max | Neuronal Differentiation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $5.00/1Box |
VIP1Y
|
Hebei Jiafan Trading Company Limited
|
2025-05-14 | |
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-07-16 | |
| $0.00/1G |
VIP1Y
|
Shenzhen Nexcon Pharmatechs Ltd.
|
2025-06-03 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY